Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Targeted Drugs R&D Services

Deeply integrate R&D experience, constantly climb the peak of R&D technology, and build an integrated innovation service platform for new drug R&D

Targeted Drugs R&D Services

Nowadays, development of targeted antitumor drugs are booming and have increased significantly year by year. The research and development of antitumor drugs fully entered the era of precise targeted therapy. Targeted tumor drugs work by targeting those differences that help a tumor cell to survive and grow. They are one of the main treatments for some cancers. For example, advanced melanoma and some types of leukaemia. There are many different types of targeted drugs, such as KRAS inhibitors, STAT3 inhibitors, GLP-1R agonists, and etc.. In addition, targeted drug delivery holds immense potential to improve the treatment of cancer by selectively providing therapeutically effective drug concentrations at the tumor site.

glp-1 new drug R&D service.webp

GLP-1 New Drug R&D Service

Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA,1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.

Learn more

Medicilon STAT3-targeted Drugs R&D Service.webp

STAT3-targeted Drugs R&D Service

As a transcription factor, STAT3 regulates a set of genes implicated in cancer cell survival, proliferation, angiogenesis, invasion, metastasis, drug resistance, and immune evasion. Medicilon provides STAT3 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, safety evaluation and other services.

Learn more

KRAS-targeted Drugs R&D Service.webp

KRAS-targeted Drugs R&D Service

In the formulation of KRAS integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers.

Learn more

Return